Inconsistent Rebound of Invasive Pneumococcal Disease in Connecticut following the Initial Phase of the SARS-CoV-2 Pandemic

Competing Interest Statement

SP is co PI on a research grant from Merck to Yale University, related to this work, and is PI on a grant from Merck to Yale University unrelated to this work, and has received travel fees from Merck. DMW has received consulting fees from Pfizer, Merck, GSK, and Matrivax for work unrelated to this project and is Principal Investigator on research grants and contracts with Pfizer and Merck to Yale University.

Funding Statement

This study was funded by a grant from Merck to Yale University.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Use of the data was approved by the institutional review board at Yale School of Medicine (IRB #2000036472) and the Connecticut Department of Public Health Human Investigations Committee reviewed this study as exempt (Protocol #150E).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes